Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, cross-sectional collection of data on active smoking, passive smoke exposure, and e-cigarette use in adults with confirmed cystic fibrosis who receive regular care at the Strasbourg Adult Cystic Fibrosis Center. Participants will be adults (≥18) with confirmed CF; patients with prior double lung transplantation are excluded. Information will be gathered by questionnaires and chart review to quantify prevalence and patterns of tobacco and vaping exposure. The findings aim to fill a gap in French data and to inform local tobacco-prevention and clinical counseling, including considerations about interactions with CFTR modulators such as Kaftrio.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient (≥ 18 years old)
* With confirmed cystic fibrosis
* Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center

Exclusion Criteria:

* Patients who have undergone a double lung transplant for cystic fibrosis.

Where it's running

• Service de Pneumologie - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Romain Kessler, MD, PhD
• Email: Romain.Kessler@chru-strasbourg.fr
• Phone: 33 3 69 55 03 77

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older

  This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07485543

• VX-272 dose escalation in healthy adults

  This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Tempe, Arizona · NCT07437105

• Dose escalation of VX-581 to check safety and drug levels in healthy adults

  The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Overland Park, Kansas · NCT07283770

• PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care

  This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.

  Recruiting CHU de Reims · Reims · NCT07274631

• Collecting sputum samples at home for cystic fibrosis patients

  This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.

  Recruiting at 4 sites University of Pennsylvania · Denver, Colorado and 3 other locations · NCT06950892

• New device for sweat testing in cystic fibrosis patients

  This study is testing a new device that measures sweat to see if it can help doctors better diagnose cystic fibrosis in patients, healthy individuals, and carriers.

  Recruiting Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Brussels · NCT06836453

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.